Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs

4 Sept 2018

Abstract excerpt

// Gizelka David-West 1,4,* , Amanda Ernlund 2,* , Abhilash Gadi 2 and Robert J. Schneider 2,3 1 Division of Gynecologic Oncology, New York University School of Medicine, New York, NY, USA 2 Department of Microbiology, New York University School of Medicine, New York, NY, USA 3 Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA 4 New York Medical College, Westchester Medical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ovarian cancer diagnosis and treatment
Share to PI3K/AKT/mTOR signaling in cancer
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30237852
DOI: 10.18632/oncotarget.25869

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAsPMID 30237852Read ↗

Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian CancerSemantic proximity Read ↗

Loss of <i>UBP1</i> drives oxaliplatin resistance through a targetable dependency on translation initiationSemantic proximity Read ↗

CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.Semantic proximity Read ↗

Ovarian Cancer—Insights into Platinum Resistance and Overcoming ItSemantic proximity Read ↗

Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment OptionsSemantic proximity Read ↗

Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene TargetsSemantic proximity Read ↗

A highly annotated database of genes associated with platinum resistance in cancerSemantic proximity Read ↗

Reduced 4E-BP1 activity leads to acquired capivasertib resistance via increased cap-dependent protein synthesisSemantic proximity Read ↗

ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer.Semantic proximity Read ↗

Identification of Three Potential Prognostic Genes in Platinum-Resistant Ovarian Cancer via Integrated Bioinformatics AnalysisSemantic proximity Read ↗

Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cellsSemantic proximity Read ↗

CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitinationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.